New Three-Drug attack on deadly skin cancer
NCT ID NCT02721459
Summary
This early-stage study aims to find the highest safe dose of a new drug called XL888 when given with two existing melanoma drugs (vemurafenib and cobimetinib). It involves 26 adults with advanced, BRAF-mutated melanoma that cannot be removed by surgery. The main goals are to determine the safest dose for future testing and to check for side effects of this three-drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.